These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7838803)

  • 1. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
    Cuneo BF; Zales VR; Blahunka PC; Benson DW
    Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
    Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
    Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.
    Adamson PC; Rhodes LA; Saul JP; Dick M; Epstein MR; Moate P; Boston R; Schreiner MS
    Pediatr Cardiol; 2006; 27(4):420-7. PubMed ID: 16835806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.
    Askenazi J; MacCosbe PE; Hoff J; Turlapaty P; Hua TA; Laddu A
    J Clin Pharmacol; 1987 Aug; 27(8):567-73. PubMed ID: 2888793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
    Barth C; Ojile M; Pearson AC; Labovitz AJ
    Am Heart J; 1991 Mar; 121(3 Pt 1):782-8. PubMed ID: 1672051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of esmolol in children.
    Wiest DB; Trippel DL; Gillette PC; Garner SS
    Clin Pharmacol Ther; 1991 Jun; 49(6):618-23. PubMed ID: 1676357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
    Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
    J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The hemodynamic effects of a treatment with beta-receptor blockers during coronary surgery. A comparison between acebutolol and esmolol].
    Kling D; Boldt J; Zickmann B; Dapper F; Hempelmann G
    Anaesthesist; 1990 May; 39(5):264-8. PubMed ID: 1972611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of esmolol in hypertension after cardiac surgery.
    Gray RJ; Bateman TM; Czer LS; Conklin C; Matloff JM
    Am J Cardiol; 1985 Oct; 56(11):49F-56F. PubMed ID: 2864849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
    Felix SB; Stangl V; Kieback A; Doerffel W; Staudt A; Wernecke KD; Baumann G; Stangl K
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):666-71. PubMed ID: 11602813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Esmolol as a bolus for prevention of sympathetic adrenergic reactions following induction of anesthesia].
    Schäffer J; Karg C; Piepenbrock S
    Anaesthesist; 1994 Nov; 43(11):723-9. PubMed ID: 7840400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
    J Cardiovasc Pharmacol; 2018 Mar; 71(3):137-146. PubMed ID: 29112591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.
    Howie MB; Hiestand DC; Zvara DA; Kim PY; McSweeney TD; Coffman JA
    Anesth Analg; 1992 Nov; 75(5):805-10. PubMed ID: 1358003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration.
    Abdullah EE; Pollick C
    Int J Card Imaging; 1997 Feb; 13(1):53-7. PubMed ID: 9080239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of esmolol given during cardiopulmonary bypass on fractional area of contraction from transesophageal echocardiography.
    Cork RC; Azari DM; McQueen KA; Aufderheide S; Mitchell M; Naraghi M
    Anesth Analg; 1995 Aug; 81(2):219-24. PubMed ID: 7618705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
    Wiest D
    Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.